BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. Since its discovery in the early 1990s it has been studied extensively in animal models for tissue healing, gut protection, and anti-inflammatory effects. This overview summarises what the published preclinical literature reports about its structure, proposed mechanisms, and safety findings.
What Is BPC-157?
BPC-157 is a 15-amino-acid peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It was first isolated and characterised by Professor Predrag Sikiric at the University of Zagreb in 1993. Unlike many synthetic peptides, it is reported to be stable in gastric acid, a property that has made its oral pharmacology a subject of study.
Over 100 peer-reviewed studies have examined BPC-157 in animal models, spanning tendon healing (Staresinic et al., 2003), muscle repair (Pevec et al., 2010), gut cytoprotection (Sikiric et al., 2018), and neuroprotection (Klicek et al., 2013). No completed human clinical trials have been published as of March 2026.
Proposed Mechanisms of Action
Preclinical research associates BPC-157 with modulation of several growth-factor and signalling pathways rather than a single receptor target. Reported mechanisms include upregulation of vascular endothelial growth factor (VEGF) and promotion of angiogenesis, interaction with the nitric oxide (NO) system, and activation of the FAK-paxillin pathway implicated in cell migration and tissue repair (Sikiric et al., 2018). These findings derive from animal and in-vitro models and have not been confirmed in humans.
Pharmacology
Pharmacokinetic modelling in animals suggests a relatively short plasma half-life, estimated in the region of 4-6 hours. Its reported stability in gastric acid distinguishes it from many peptides that are rapidly degraded in the digestive tract, which is why both parenteral and oral pharmacology have been examined in the literature (Sikiric et al., 2018). BPC-157 is typically supplied for laboratory work as a lyophilised (freeze-dried) powder.
Safety Findings in the Literature
BPC-157 has shown a favourable safety profile in animal toxicity studies, with rodent studies reporting no adverse effects at exposures well above those used in efficacy models (Sikiric et al., 2006). Because BPC-157 influences angiogenic signalling (VEGF, NO, FAK-paxillin), the literature notes a theoretical caution around conditions involving abnormal vascularisation; no direct evidence of tumour promotion has been published, and this remains a precautionary observation rather than a finding.
Related Compounds
In the research literature BPC-157 is frequently studied alongside TB-500 (Thymosin Beta-4), which acts through actin regulation rather than growth-factor modulation. The two are often compared for their complementary mechanisms in tissue-repair models.
Key References
- Sikiric, P. et al. (2018). "Brain-gut axis and pentadecapeptide BPC 157." Current Neuropharmacology, 16(5), 512-533.
- Staresinic, M. et al. (2003). "Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon." Journal of Orthopaedic Research, 21(6), 976-983.
- Pevec, D. et al. (2010). "Impact of pentadecapeptide BPC 157 on muscle healing." Journal of Physiology and Pharmacology, 61(2), 177-183.
- Sikiric, P. et al. (2006). "Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157." Current Pharmaceutical Design, 12(30), 4051-4067.